Company Profile
Genprex Stock Price, News & Catalysts
- Ticker:
- GNPX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.63 USD (+2.73%)
Close
Last updated: October 2, 2026
7.78M USD
Market cap
Why the stock is moving
As of Oct 2, 2026, GNPX closed up 2.73% at $2.63. No new same-company headline was identified in the current news window.
Company overview
Gene Therapy Company
Genprex develops gene therapies for cancer and diabetes. Its platform uses non-viral nanoparticles to deliver tumor-suppressor genes systemically and separate gene constructs intended to restore insulin production.
REQORSA Tumor-Suppressor Therapy
REQORSA, or quaratusugene ozeplasmid, delivers the TUSC2 tumor-suppressor gene in a lipid nanoparticle. The therapy is designed to restore anticancer signaling and make tumors more responsive to targeted therapy or immunotherapy.
Acclaim Lung Cancer Programs
Acclaim-1 combines REQORSA with osimertinib in EGFR-mutated non-small cell lung cancer after progression on Tagrisso. Acclaim-3 evaluates REQORSA with atezolizumab in extensive-stage small cell lung cancer.
Biomarker-Guided Development
Genprex is working with Roche to validate biomarkers that may identify patients most likely to benefit from REQORSA combinations. A clearer biomarker strategy could guide enrollment and interpretation of later clinical studies.
Diabetes Gene Therapy Portfolio
The company also owns preclinical diabetes programs designed to convert pancreatic cells into insulin-producing cells. These assets broaden the platform beyond oncology but remain earlier in development.
Future catalysts
- Completion of the REQORSA biomarker-validation work with Roche around the end of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Genprex (GNPX)?
Genprex (GNPX) most recently closed at 2.63 USD, a +2.73% move versus the previous session.
What is the market cap of Genprex (GNPX)?
Genprex currently has a market capitalization of 7.78M USD on BioPharmSignal.
What does Genprex do?
Gene Therapy Company Genprex develops gene therapies for cancer and diabetes. Its platform uses non-viral nanoparticles to deliver tumor-suppressor genes systemically and separate gene constructs intended to restore insulin production. REQORSA Tumor-Suppressor Therapy REQORSA, or quaratusugene ozeplasmid, delivers the TUSC2 tumor-suppressor gene in a lipid...
On which exchange is GNPX stock listed?
Genprex (GNPX) is associated with NASDAQ, United States, Biopharma.
What is osimertinib?
Acclaim Lung Cancer Programs Acclaim-1 combines REQORSA with osimertinib in EGFR-mutated non-small cell lung cancer after progression on Tagrisso.
Which conditions is Genprex targeting with osimertinib?
Genprex is associated with oncology, cancer therapeutics, diabetes based on its company overview and current catalyst commentary.
How does Genprex describe recent progress with osimertinib?
Completion of the REQORSA biomarker-validation work with Roche around the end of 2026.
What is atezolizumab?
Acclaim-3 evaluates REQORSA with atezolizumab in extensive-stage small cell lung cancer.